Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Chief Financial Officer | March 14, 2024 | March 15, 2024 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | VP,Finance & Princ.Acctg. Off. | May 14, 2020 | May 16, 2020 |
| Rain Oncology Inc.RAIN · Entity 94695 | VP of Finance & Admin | February 15, 2023 | February 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lexaria Bioscience Corp.
Report date March 14, 2024 · Filed March 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.93 · Expires 2029-03-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-03-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 50,000 options are exercisable on March 15, 2024, an additional 50,000 options are exercisable on March 15, 2025, thereafter an additional 4,166 options are exercisable monthly until Feb. 15, 2027 with the balance of 4,182 options being exercisable on March 15, 2027 |
Filing footnotes · ownership attribution and instrument terms
F1: 50,000 options are exercisable on March 15, 2024, an additional 50,000 options are exercisable on March 15, 2025, thereafter an additional 4,166 options are exercisable monthly until Feb. 15, 2027 with the balance of 4,182 options being exercisable on March 15, 2027
RIGEL PHARMACEUTICALS INC
Report date May 14, 2020 · Filed May 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2030-05-14 | Direct | 20,000 |
Reported balance
After 2020-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-14 · Grant · Acquired 20,000 · Balance 20,000 F1: Fifty per cent (50%) of the shares subject to the option shall vest one year from the date of grant and fifty per cent (50%) of the shares subject to the option shall vest shall vest two years from the date of grant, subject to the reporting person's continuous service to the issuer through each such period. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty per cent (50%) of the shares subject to the option shall vest one year from the date of grant and fifty per cent (50%) of the shares subject to the option shall vest shall vest two years from the date of grant, subject to the reporting person's continuous service to the issuer through each such period.
Rain Oncology Inc.
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.30 · Expires 2033-02-15 | Direct | 65,325 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 65,325 · Balance 65,325 F1: This option represents a right to purchase a total of 65,325 shares of the Issuer's common stock, one quarter of which will vest on February 15, 2024, with the remaining three quarters vesting in equal monthly installments through February 15, 2027, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 65,325 shares of the Issuer's common stock, one quarter of which will vest on February 15, 2024, with the remaining three quarters vesting in equal monthly installments through February 15, 2027, subject to the Reporting Person's continued service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 17, 2023 18:23 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 65,325 | $0.00 Strike: $9.30 | $0.00 |
DisclosureSEC source: 0001104659-23-023389 · tm237300-1_4seq1.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · VP of Finance & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,325 Underlying: Common Stock · 65,325 shares Expires 2033-02-15 F1 · derivative.exercise_date: This option represents a right to purchase a total of 65,325 shares of the Issuer's common stock, one quarter of which will vest on February 15, 2024, with the remaining three quarters vesting in equal monthly installments through February 15, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 07, 2022 Filed Feb 4, 2022 16:45 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0000899243-22-004838 · doc4.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2032-01-07 F1 · derivative.exercise_date: This option represents a right to purchase a total of 32,000 shares of the Issuer's common stock, one quarter of which will vest on January 7, 2023, with the remaining three quarters vesting in equal monthly installments through January 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 12, 2021 Filed May 14, 2021 18:37 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $15.91 | $0.00 |
DisclosureSEC source: 0000899243-21-019568 · doc4.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-05-12 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,000 shares of the Issuer's common stock, which will vest in equal monthly installments through May 12, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 14, 2020 Filed May 16, 2020 00:57 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001179110-20-006136 · edgar.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · VP,Finance & Princ.Acctg. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-14 F1 · derivative.exercise_date: Fifty per cent (50%) of the shares subject to the option shall vest one year from the date of grant and fifty per cent (50%) of the shares subject to the option shall vest shall vest two years from the date of grant, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:31 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001179110-20-001351 · edgar.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · VP,Finance & Princ.Acctg. Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:55 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000940 · edgar.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 22:46 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 10,000 | $3.12 | $31,200.00 |
DisclosureSEC source: 0001179110-18-012211 · edgar.xml · nonDerivative · entry 1 Cabatuan Nelson · CIK 0001725908 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58 F1 · kind: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 5, 2018. F2 · shares: Includes Reporting Person's purchases of 5,000 shares on December 29, 2017 and 5,000 shares on June 26, 2018 under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 22:16 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001179110-18-010636 · edgar.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-08-14 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over forty-eight (48) months from the vesting commencement date of August 14, 2018. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 23:44 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-18-001146 · edgar.xml · derivative · entry 1 Cabatuan Nelson · CIK 0001725908 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.